<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706663</url>
  </required_header>
  <id_info>
    <org_study_id>10000048</org_study_id>
    <secondary_id>000048-C</secondary_id>
    <nct_id>NCT04706663</nct_id>
  </id_info>
  <brief_title>Precision-Based Genomics in Prostate Cancer</brief_title>
  <official_title>A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Prostate cancer is the most common cancer and the second leading cause of death in males in&#xD;
      the United States. Researchers want to find additional gene mutations that may increase a man&#xD;
      s risk for prostate cancer and may affect how aggressive the disease is.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To look at gene mutations in men with prostate cancer as well as the course of their disease&#xD;
      to better understand how gene mutations relate to the way the cancer progresses and responds&#xD;
      to treatment.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Adult males 18 and older with prostate cancer who have at least one of the gene mutations&#xD;
      researchers want to study and/or have been treated for their cancer and have had complete&#xD;
      elimination of their cancer or stable disease for a long time.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with a review of their medical records. Their gene test results&#xD;
      will be reviewed, if available. They will be asked questions over the phone or in person.&#xD;
&#xD;
      Participants do not need to visit the NIH for this study. But if they visit NIH for another&#xD;
      study, their data and test results will be collected. They may give blood and urine samples.&#xD;
      They may give leftover tumor samples. These samples will be used to study their genes.&#xD;
&#xD;
      Participants who do not come to NIH on regular basis will be contacted every 6 months by&#xD;
      phone or e-mail. They will be asked questions about their health. Data from their medical&#xD;
      records will be collected.&#xD;
&#xD;
      Participants will have testosterone and prostate-specific antigen (PSA) tests.&#xD;
&#xD;
      Participants may be invited to NIH to give blood samples for research.&#xD;
&#xD;
      Participants on this study will be followed for life....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Prostate cancer is the most common cancer and the second leading cause of death in males&#xD;
           in the United States with an estimated 191,930 new cases and 33,330 deaths in 2020.&#xD;
&#xD;
        -  There has been progress in identifying established risk factors for the development of&#xD;
           prostate cancer, including genetic predisposition. The study of the molecular genetics&#xD;
           of prostate cancer has identified pathogenic variants, such as BRCA1 and BRCA2&#xD;
           (associated with hereditary breast and ovarian cancer syndrome), HOXB13 (associated with&#xD;
           hereditary prostate cancer), and DNA mismatch repair (MMR) gene variants (MLH1, MSH2,&#xD;
           MSH6, PMS2, and EPCAM) associated with Lynch syndrome.&#xD;
&#xD;
        -  While our understanding of molecular genetics continues to grow, there remains a need to&#xD;
           identify additional germline and somatic mutations and alterations that may increase an&#xD;
           individual s risk to develop prostate cancer and potentially the aggressiveness of the&#xD;
           disease. In studying the following alterations in prostate cancer, in both localized and&#xD;
           advanced stages, potential expanded molecular findings may lead to actionable&#xD;
           therapeutic targets and biomarker development. A better understanding of molecular&#xD;
           genetics in a longitudinal study of subjects with prostate cancer may be helpful for the&#xD;
           design of future treatment studies, and to develop a better understanding of the natural&#xD;
           history of the disease&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To longitudinally evaluate subjects with prostate cancer with known germline and/or&#xD;
           somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP,&#xD;
           Wnt/B-catenin pathway, and MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM to better&#xD;
           understand the natural history of the disease.&#xD;
&#xD;
        -  To longitudinally evaluate subjects with tumor mutational burden-high (TMB-H) prostate&#xD;
           cancer [greater than or equal to 10 mutations/megabase (mut/Mb)].&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Subjects with histologically confirmed prostate cancer&#xD;
&#xD;
        -  Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1,&#xD;
           RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, and MMR genes: MLH1, MSH2, MSH6,&#xD;
           PMS2, and EPCAM and/or TMB-high or be deemed an exceptional responder. NOTE: any&#xD;
           platform for genomics testing is acceptable (research or CLIA-certified)&#xD;
&#xD;
        -  Age greater than or equal to 18 years old&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This will be a long-term multi-center study to comprehensively study participants with&#xD;
           prostate cancer.&#xD;
&#xD;
        -  Participants will provide clinical information (including medical history, clinical&#xD;
           tests, imaging studies and reports, surgical pathology reports, genetic test results).&#xD;
&#xD;
        -  Since long-term follow-up of individuals with prostate cancer is a major feature of the&#xD;
           study, local sites intend to maintain active contact with study subjects for as long as&#xD;
           possible. Participants will be followed throughout the course of their illnesses, with&#xD;
           particular attention to patterns of disease recurrence and progression, response to&#xD;
           therapies and duration of responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>natural history of prostate cancer with known germline and/or somatic variants</measure>
    <time_frame>ongoing</time_frame>
    <description>clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>natural history of TMB-H prostate cancer</measure>
    <time_frame>ongoing</time_frame>
    <description>clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Subjects with histologically confirmed prostate cancer and genomic testing results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary clinical&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Subjects with histologically confirmed prostate cancer.&#xD;
&#xD;
          -  Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1,&#xD;
             RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, and/or MMR genes: MLH1, MSH2,&#xD;
             MSH6, PMS2, and EPCAM and/or TMB-high([defined as greater than or equal to 10&#xD;
             mutations/megabase (mut/Mb)]. NOTE: any platform for genomics testing is acceptable&#xD;
             (research or CLIA-certified)&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  be deemed an exceptional responder. NOTE: an exceptional response is defined as&#xD;
             achievement of either a) a complete response, or b) a confirmed partial response in a&#xD;
             trial or treatment or a response of exceptionally long duration&#xD;
&#xD;
          -  Age greater than or equal to 18 years old.&#xD;
&#xD;
          -  Ability of subject to understand and the willingness to sign a written informed&#xD;
             consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        -None&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L Dahut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine O Lee-Wisdom, R.N.</last_name>
    <phone>(240) 858-3525</phone>
    <email>katherine.lee-wisdom@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rana McKay</last_name>
      <phone>858-657-7876</phone>
      <email>rmckay@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Small</last_name>
      <phone>415-353-7095</phone>
      <email>Eric.Small@uscf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lurie Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Hussain</last_name>
      <phone>312-926-2413</phone>
      <email>maha.huss@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Lee-Wisdom, B.S.N.</last_name>
      <phone>240-858-3525</phone>
      <email>katharyn.wisdom@nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute, Boston ,MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Himisha Beltran</last_name>
      <phone>617-632-2429</phone>
      <email>Himisha_Beltran@DFCI.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arul Chinnaiyan</last_name>
      <phone>734-647-8903</phone>
      <email>arul@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Oh</last_name>
      <phone>212-241-6756</phone>
      <email>William.Oh@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wassim Abida</last_name>
      <phone>646-422-4633</phone>
      <email>abidam@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cora Sternberg</last_name>
      <phone>646-962-2072</phone>
      <email>cns9006@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Graff</last_name>
      <phone>503-494-6594</phone>
      <email>graffj@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>28104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Montgomery</last_name>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Montgomery</last_name>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Montgomery</last_name>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000048-C.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>October 5, 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>germline variants</keyword>
  <keyword>somatic variants</keyword>
  <keyword>Genetic Predisposition</keyword>
  <keyword>Molecular Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

